Terms ending in 2040
Every in-force patent on Intervet Inc.'s record whose computed term ends in 2040, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,548,859 | Method for Producing (5,S)-4-[5-(3,5-Dichlorophenyl)-5-(TRIFLUOROMETHYL)-4HISOXAZOL-3-YL]-2-Methyl-BENZOIC Acid In force · High confidence | Intervet Inc. | In force | High confidence | |
| US 11,858,904 | Process for Preparing Large Size Isoxazoline Particles In force · High confidence | Intervet Inc. | In force | High confidence | |
| US 12,239,704 | Recombinant Non-Pathogenic Marek's Disease Virus Constructs Encoding Multiple Heterologous Antigens In force · High confidence | Intervet Inc. | In force | High confidence | |
| US 12,697,323 | Implantable Isoxazoline Pharmaceutical Compositions and Uses Thereof In force · High confidence | Intervet Inc. | In force | High confidence | |
| US 12,721,839 | Soft Chewable Veterinary Dosage Form In force · Medium confidence | Intervet Inc. | In force | Medium confidence | |
| US 12,721,885 | A Novel Vaccine Against Heamophilus Parasuis In force · Low confidence | Intervet Inc. | In force | Low confidence |
6 of 6 patents shown. Soonest term end first, then patent number.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.